AIM News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AI

Mkt Cap

$6.8M

Volume

336.75K

Next Earnings

November 16th

Chart Financials Earnings News About Insider Filings

AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041AIM ImmunoTech announced patent protection for Ampligen across 18 European countries and the United Kingdom through June 2041 for Long COVID treatment. The company also recently secured a U.S. patent for Ampligen combined with pembrolizumab for cancer treatment. These patents strengthen AIM's global intellectual property position around its dsRNA immunomodulator platform across multiple therapeutic indications.GlobeNewswire Inc. · Sep 2, 2026

AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private PlacementAIM ImmunoTech Inc. announced a $2.4 million financing consisting of a registered direct offering of 7.5 million shares at $0.325 per share and concurrent private placement of Series I Warrants to purchase 15 million shares. The company plans to use proceeds for manufacturing clinical drug supply, Phase 3 clinical trial activities, and working capital. The offering is expected to close on May 21, 2026.GlobeNewswire Inc. · May 20, 2026

AIM ImmunoTech Provides Routine Update on Annual FilingsAIM ImmunoTech Inc. disclosed that its 2025 audited financial statements contain a going concern emphasis of matter from its independent auditors. Despite this, management expressed confidence in its ability to raise funds based on positive progress in Phase 2 clinical trials of its lead drug Ampligen combined with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer. The company expects to release the next DURIPANC study update in June 2026.GlobeNewswire Inc. · Apr 13, 2026

Why Is AIM ImmunoTech Stock Gaining Today?AIM ImmunoTech stock surged 73.66% to $1.21 after securing full approval for a Japanese patent protecting the use of Ampligen combined with checkpoint inhibitors for cancer treatment, particularly pancreatic cancer. The patent extends through December 2039, strengthening the company's intellectual property position in a major global pharmaceutical market. AIM plans to pursue orphan drug designation in Japan and already holds similar designations in the U.S. and EU.Benzinga · Mar 18, 2026

AIM ImmunoTech Announces Closing of its Rights OfferingAIM ImmunoTech Inc. announced the closing of its rights offering, which raised approximately $1.8 million. The offering allowed investors to purchase units consisting of Series G Convertible Preferred Stock and Class G Common Stock Purchase Warrants. The company is focused on developing Ampligen (rintatolimod) for treating late-stage pancreatic cancer.GlobeNewswire Inc. · Mar 7, 2026

AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 MillionAIM ImmunoTech announced the expiration of its rights offering on March 3, 2026, which generated approximately $1.8 million in gross proceeds. The offering allowed shareholders to purchase units consisting of Series G Convertible Preferred Stock and Class G Common Stock Purchase Warrants at $1,000 per unit. The company expects the offering to close on or about March 6, 2026.Benzinga · Mar 4, 2026

AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights OfferingAIM ImmunoTech Inc. announced a rights offering expected to raise $12 million in gross proceeds. Shareholders of record as of February 4, 2026 will receive one non-transferable subscription right per share to purchase units consisting of Series G Convertible Preferred Stock and warrants at $1,000 per unit. The subscription period runs from February 5-23, 2026. Net proceeds will fund clinical trials, manufacturing expenses for pancreatic cancer trials, and debt repayment.GlobeNewswire Inc. · Jan 23, 2026

AIM ImmunoTech Announces Stock DividendAIM ImmunoTech Inc. announced a stock dividend of one share for every 1,000 outstanding shares of common stock, as well as one share for every outstanding option or warrant. The dividend is payable to shareholders of record on January 9, 2026, with distribution to DTCC on January 13, 2026. Fractional shares will be rounded down with cash compensation at $1.305 per share.Benzinga · Dec 30, 2025

AIM ImmunoTech Announces Stock DividendAIM ImmunoTech Inc. announced a stock dividend of one share per 1,000 outstanding shares, with a record date of January 9, 2026 and distribution date of January 13, 2026. Fractional shares will be paid in cash at $1.305 per share. The company is an immuno-pharma firm developing therapeutics for cancers, immune disorders, and viral diseases, with its lead product being Ampligen (rintatolimod).GlobeNewswire Inc. · Dec 30, 2025

Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443BEmerging immunotherapy technologies are transforming treatment for gastrointestinal cancers, with companies developing novel combination strategies to activate immune responses in historically resistant tumors. The global cancer immunotherapy market is projected to reach $443.17 billion by 2030.Benzinga · Dec 16, 2025

AI

AIMAIM ImmunoTech Inc.

AIM

Pay with—

Available Balance0.00

Your PositionYou don't own any AIM yet.

Related Tickers

Earnings